2019
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal Of The American Society Of Nephrology 2019, 15: 289-297. PMID: 31836598, PMCID: PMC7015091, DOI: 10.2215/cjn.08580719.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationKidney injuryHepatic sinusoidal obstruction syndromeAcute kidney injurySinusoidal obstruction syndromeCongenital immune deficiencyDevelopment of CKDType of transplantNonmalignant hematologic disordersStem cell transplantLife-saving therapySickle cell diseaseHigh mortality rateAcute dialysisNephrotoxic medicationsNonrelapse mortalityConditioning regimenHost diseaseInfusion syndromeObstruction syndromeThrombotic microangiopathyTransplant recipientsPatient characteristics
2015
Drug-Induced Glomerular Disease: Direct Cellular Injury
Markowitz GS, Bomback AS, Perazella MA. Drug-Induced Glomerular Disease: Direct Cellular Injury. Clinical Journal Of The American Society Of Nephrology 2015, 10: 1291-1299. PMID: 25862776, PMCID: PMC4491280, DOI: 10.2215/cjn.00860115.Peer-Reviewed Original ResearchConceptsGlomerular diseaseCell injuryGlomerular lesionsNonsteroidal anti-inflammatory drugsAcute interstitial nephritisDrug-induced etiologyPotential of medicationsRenal function recoveryAcute tubular necrosisEndothelial cell injuryMesangial cell injuryEpithelial cell injuryAnti-inflammatory drugsDirect cellular injuryRapid discontinuationKidney injuryTubular necrosisAntiplatelet agentsInterstitial nephritisTubulointerstitial compartmentFunction recoveryIatrogenic formCellular injuryAntiangiogenesis drugsInjury
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2000
Drug-induced hyperkalemia: old culprits and new offenders
Perazella M. Drug-induced hyperkalemia: old culprits and new offenders. The American Journal Of Medicine 2000, 109: 307-314. PMID: 10996582, DOI: 10.1016/s0002-9343(00)00496-4.Peer-Reviewed Original ResearchConceptsDrug-induced hyperkalemiaRisk of hyperkalemiaRenal potassium excretionRenal impairmentPatient characteristicsPotassium excretionPotassium handlingPotassium loadPrescribed medicationsExcessive ingestionHyperkalemiaCounter drugsOld culpritsNutritional supplementsPotassium homeostasisMedicationsPatientsDrugsCellular uptakeInfusionAbnormalitiesExcretionPhysiciansImpairmentIngestion